Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.80 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.80 |
| ▸ | AURKA | O14965 | 15/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757479 | 0.94 | LCK (0.70) | LCKTNK2AURKAAURKBEGFR | |
| SCHEMBL757476 | 0.93 | AURKA (0.74) | LCKTNK2AURKAAURKBEGFR | |
| SCHEMBL757804 | 0.93 | AURKA (0.72) | LCKTNK2AURKAAURKBEGFR | |
| SCHEMBL757445 | 0.92 | AURKA (0.79) | LCKTNK2AURKAAURKB | |
| SCHEMBL759209 | 0.92 | AURKA (0.69) | LCKTNK2AURKAAURKB | |
| SCHEMBL757440 | 0.89 | AURKA (0.85) | LCKTNK2AURKAAURKB | |
| SCHEMBL2967328 | 0.89 | TNK2 (1.00) | LCKTNK2AURKAEGFRSRC | |
| SCHEMBL759066 | 0.87 | AURKA (0.69) | LCKTNK2AURKAAURKB | |
| SCHEMBL759064 | 0.87 | AURKA (0.69) | LCKTNK2AURKAAURKB | |
| SCHEMBL759205 | 0.86 | AURKA (0.78) | LCKTNK2AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2009134658-A2 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | AURKB, AURKA, AURKC | LCK 503/4885TNK2 193/4885AURKA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.